Dapagliflozin (DAPA)

DRUG18 trials

Conditions

Acute Decompensated Heart Failure (ADHF)AlbuminuriaAnemiaAnemia, Kidney Disease, ChronicArrhythmias, CardiacAtrial Fibrillation (AF)CKDCOVID - 19

Early Phase 1

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

CompletedNCT06812429

Washington University School of MedicineInflammation

Start: 2024-05-08End: 2025-04-05Updated: 2026-01-07

Phase 1

Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation

Not yet recruitingNCT06759909

Assiut UniversityAtrial Fibrillation (AF), Dapagliflozin (Forxiga)

Start: 2025-01-03End: 2028-12-22Target: 100Updated: 2025-01-06

Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).

Active, not recruitingNCT07020377

Amira Bisher,PhDDiabetes Mellitus, Non Alcholic Fatty Liver Disease

Start: 2024-01-15End: 2025-12-30Target: 60Updated: 2025-06-13

Phase 2

Dapagliflozin in Allo-HCT for aGVHD

RecruitingNCT06626737

The First Affiliated Hospital of Soochow UniversityGraft-versus-host Disease (GVHD)

Start: 2025-04-26End: 2026-12-31Target: 72Updated: 2025-06-05

Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia

Active, not recruitingNCT06748105

Lauro Fabián Amador MedinaDapagliflozin (Forxiga), Glucocorticoid, Hyperglycaemia

Start: 2024-12-01End: 2025-12-01Target: 38Updated: 2024-12-27

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

RecruitingNCT06897605

Mansoura UniversityAnemia, Kidney Disease, Chronic, Chronic Kidney Disease(CKD)

Start: 2025-04-01End: 2025-10-31Target: 80Updated: 2025-04-02

Phase 3

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

CompletedNCT02635386

Woman'sObesity, Polycystic Ovary Syndrome

Start: 2016-03-22End: 2020-10-09Updated: 2021-01-29

Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

Active, not recruitingNCT06759077

Al-Azhar UniversityKidney Diseases

Start: 2024-12-28End: 2025-12-28Updated: 2025-01-08

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

Not yet recruitingNCT06820567

Assiut UniversityChronic Kidney Diseases, Diabetes Type 2

Start: 2025-03-01End: 2027-05-01Target: 210Updated: 2025-02-11

Dapagliflozin for Long COVID Syndrome

Not yet recruitingNCT06907251

Ottawa Heart Institute Research CorporationCOVID - 19, Long COVID Syndrome, SARS CoV-2

Start: 2026-04-01End: 2029-06-30Target: 192Updated: 2026-02-20

A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

RecruitingNCT07082114

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2025-07-14End: 2027-05-17Target: 800Updated: 2025-07-24

Phase 4

Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study

CompletedNCT06721442

Beneficência Portuguesa de São PauloArrhythmias, Cardiac, Diabetes Mellitus

Start: 2023-01-10End: 2024-07-10Updated: 2024-12-06

Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

Not yet recruitingNCT06922656

Dasman Diabetes InstituteType 1 Diabetes

Start: 2025-09-15End: 2027-01-15Target: 60Updated: 2025-08-29

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Enrolling by invitationNCT06954090

Steno Diabetes Center CopenhagenAlbuminuria, Type 2 DM, Type 2 DM /Diabetic Nephropathy

Start: 2025-11-20End: 2027-05-31Target: 50Updated: 2025-12-22

The Effect of Dapagliflozin on Patients With Cardiomyopathy

RecruitingNCT07076615

May Mohamed AbdallaAcute Decompensated Heart Failure (ADHF)

Start: 2025-08-31End: 2026-05-31Target: 100Updated: 2025-08-22

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

CompletedNCT07120828

Erbil Polytechnic UniversityObese Diabetics, Obese Patients (BMI ≥ 30 kg/m²), Type 2 Diabetes

Start: 2025-07-15End: 2026-03-15Updated: 2026-03-17

Unknown Phase

The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

CompletedNCT06778330

Fayoum UniversityHeart Failure NYHA Class II

Start: 2025-01-20End: 2025-08-01Updated: 2025-09-03

Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

Active, not recruitingNCT06813222

Damanhour UniversityAnemia, CKD

Start: 2021-04-01End: 2025-03-01Target: 100Updated: 2025-02-06

Related Papers

Effect of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on ventricular repolarization electrocardiographic parameters in type 2 diabetes patients: DAPA - ECG study

Frontiers in Clinical Diabetes and Healthcare2025-03-311 citations